Quest Diagnostics in the news
Extensive clinical diagnostic testing
Tamtam found 20 recent articles about Quest Diagnostics.
- Quest Diagnostics SVP Plewman sells $3.01 million in stock By Investing.com
Quest Diagnostics' SVP sold $3.01 million in stock after exercising options, as the company's stock trades near a 52-week high following strong Q3 2026 results.
- Under trading plans, Quest Diagnostics (DGX) SVP sells 11,717 shares at $257.34.
Quest Diagnostics' SVP of Diagnostic Services sold over 11,000 shares of company stock at $257.34 per share through a pre-planned trading arrangement.
- Quest Diagnostics stock hits all-time high at 261.58 USD By Investing.com
Quest Diagnostics' stock reached an all-time high, driven by strong Q3 2026 financial results that exceeded expectations and an uplifted full-year outlook.
- Quest Diagnostics stock faces compliance overhang after settlement
Quest Diagnostics settled allegations of improper incentives to healthcare providers for 13.014576 million USD, agreeing to a five-year federal Corporate Integrity Agreement.
- Quest Diagnostics (NYSE:DGX): A Quality Dividend Stock for Income Investors
Quest Diagnostics is presented as a quality dividend stock due to its strong dividend profile, profitability, and financial health, making it suitable for income investors.
- Quest Diagnostics (DGX) Declares Quarterly Dividend, Is The Stock Fully Priced?
Quest Diagnostics declared a quarterly dividend while its stock shows recent gains but is deemed slightly overvalued amidst new digital health offerings and potential reimbursement challenges.
- What Happened To People Who Bought Quest Stock At A High?
Quest Diagnostics stock hit a 52-week high due to strong earnings and a higher valuation multiple, and historical data suggests buying at a high has generally yielded positive returns over a year.
- Quest Diagnostics (DGX) Declares $0.86 Quarterly Dividend; 1.3% Yield
Quest Diagnostics announced a quarterly dividend of $0.86 per share, resulting in an annual yield of 1.3%.
- Quest Diagnostics declares $0.86 quarterly dividend By Investing.com
Quest Diagnostics declared a quarterly cash dividend of $0.86 per share, payable on January 27, 2027, to shareholders of record as of January 12, 2027.
- Quest Diagnostics Declares Quarterly Cash Dividend
Quest Diagnostics announced a quarterly cash dividend of $0.86 per share, payable on January 27, 2027.
- Lab company Quest pays $13 million to settle Medicare fraud lawsuit
Quest Diagnostics settled a lawsuit for $13 million over alleged Medicare and Medicaid fraud involving client referrals exchanged for exclusive entertainment at MetLife Stadium.
- Quest Diagnostics to Speak at the Jefferies Global Healthcare Conference in London
Quest Diagnostics' CFO will speak at the Jefferies Global Healthcare Conference in London on November 17, 2026, with a live webcast available.
- Quest Diagnostics pays more than $13M to settle alleged kickback scheme, federal prosecutors say
Quest Diagnostics paid over $13 million to settle claims of providing VIP New York Giants tickets to hospital executives for lab service referrals.
- Quest Diagnostics pays $13M to settle allegations tied to Giants ticket perks
Quest Diagnostics paid over $13 million to settle allegations of federal anti-kickback law violations for offering entertainment perks to healthcare providers in exchange for testing referrals.
- Quest Diagnostics pays $13M to settle kickback allegations involving NY Giants tickets
Quest Diagnostics settled kickback allegations for over $13 million, involving New York Giants tickets given to healthcare providers for referrals.
- Quest Diagnostics, Name on Giants' Practice Complex, Settles Federal Kickback Claims for $13M
Quest Diagnostics paid over $13 million to settle federal kickback claims for using Giants tickets and VIP events to gain referrals.
- NJ-Based Quest Diagnostics Pays $13M to Settle Allegations of Illegal Perks at Giants Games
Quest Diagnostics settled for over $13 million federal allegations of providing illegal luxury entertainment perks to healthcare professionals for patient referrals.
- Lab giant to pay $13M settlement over charges it used MetLife events to drum up new business
Quest Diagnostics will pay over $13 million to settle claims it offered illegal kickbacks, like exclusive sports entertainment, to healthcare providers to boost referrals.
- Secaucus Lab Giant Quest Diagnostics Pays $13M Over Giants Suite Kickback Claims
Quest Diagnostics paid over $13 million to resolve allegations of offering free New York Giants perks to healthcare providers in exchange for laboratory testing referrals.
- IBD Stock Of The Day Bucks Postelection Medtech Malaise
Quest Diagnostics is recognized as a strong defensive growth stock in the medical sector with high ratings and a positive chart pattern.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Quest Diagnostics?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies